Hyundai Hope on Wheels Bridge to K Award for NIH K Award Applicants

Purpose

• The purpose of the Hyundai Bridge2K Award is to provide seed funding to support the resubmission efforts of strong pediatric cancer-focused grant applications that narrowly missed the pay line at national funding agencies. *Ideal candidates are those with NIH K award applications (e.g., K08, K23) that were scored.*

Application Details

• The Hyundai Bridge2K Award is a $150,000, one-year award. Approved funding may be used only for the purposes expressly set forth in the applicant’s proposal and specifically performed under the auspices of the PI identified in the proposal.

Eligibility Criteria

• Applicants for the Hyundai Bridge2K Award must:
  
  o hold either an MD or MD/PhD degree
  
  o be a Pediatric Oncologist in a pediatric cancer-focused division with a junior faculty position (no higher than Assistant Professor) at a COG member institution
  
  o have submitted a pediatric cancer-related K award application (K08, K23, K99/R00) within the past 18 months that was scored but not funded (the 18 months begins at review date)

• There is no requirement for matching funds from the institution, but there must be demonstrated commitment of support for the career development of the applicant, including a letter from the Chief of Pediatric Hematology-Oncology and/or the Chair of the Department of Pediatrics documenting the commitment of appropriate space to perform the proposed research, protected time and any other funding to support the effort of the investigator to pursue an NIH K award or similar career development award from a federal agency. The letter should describe support
by a mentoring committee that will assist in the resubmission, the timeline for resubmission, and also briefly summarize the applicant’s response to the critiques of the initial submission of the K award application.

- The applicant can have no more than $250K annually in other research funding, and must not have previously received a Hyundai Bridge2K award. Up to two submissions for Bridge2K funding are allowed.

- The applicant must not have concurrent HHOW funding at the time of the award.

- In the event that a resubmitted K award is chosen for funding by the NIH, the applicant must immediately notify HHOW. If the timing of K award funding overlaps with Hyundai Bridge2K award support by 6 months or more, the applicant and mentor must describe overlap, including a budget demonstrating how Hyundai Bridge2K funds will be redirected to support the research (or, alternatively, describe a planned return of funds to HHOW). If the overlap of funds is less than 6 months, the applicant may use Hyundai Bridge2K funds to support their research.

**Award Description**

- Awards will be funded at $150,000 / year for one year with an additional 10% allowed for indirect costs (i.e. $15,000)

- Funds must be expended within the 12-month funding period, as no-cost extensions will not be granted.

- Allowable expenses include:
  - PI salary and fringe benefits
  - Salary and fringe benefits of research personnel
  - Research supplies
  - NO equipment or travel are permitted

- Hyundai Bridge2K funding is NOT transferable to another institution or another individual – if the recipient changes institutions during the period of support by a
Hyundai Bridge2K award, or if the recipient transitions to a non-research position, any unspent funds must be returned to HHOW.

- A final progress report must be submitted to Hyundai HHOW within 60 days of the end of the award period, detailing the number of grants applied for and obtained, number of publications/abstracts, and a full financial report detailing expenditures and variances to the budget.

- Clinical research studies or medical trials are not eligible for consideration. Eligible projects must be those with a translational impact on research. Support will not be provided for clinical trials or correlative biological studies in a clinical trial.

Application Process
The Hyundai Bridge2K Grant application, as well as all supporting documents outlined below, must be submitted online through Proposal Central.

All applications must include the following:

- **An executive summary** not exceeding 3,000 characters or 1 page that states project aims, outcomes, and benefits to pediatric cancer. The executive summary should also include brief bulleted statements in lay language on the goals of the project. These will be used to describe approved projects in HHOW websites and promotional materials.

- Specific Aims page from the original NIH K award application

- Complete Summary Statement from the original NIH K award application

- Detailed, point-by-point response to critiques from the original NIH K award application (not to exceed 5 pages)

- Documentation from NIH confirming that the K Award score was outside of the fundable range

- Completed Application in Proposal Central, including a technical abstract, lay abstract, description of significance to pediatric cancer, budget, budget
justification, details regarding other support (all current and pending grant awards), listing of key personnel and their roles on the project

- Applicant’s NIH Biographical Sketch, and NIH Biographical Sketch of Key personnel

- Institutional Commitment Letter from Pediatric Hematology-Oncology Division Chief and Pediatrics Department Chair, including description of the mentoring committee working with the PI and how they will assist the investigator in preparing for the resubmission of the NIH K award application, and the timeline for submission

- Institution W9, IRS Determination Letter, PI photo

- A HHOW grant agreement is required to be executed for all approved grants. No changes, of any sort, to the HHOW grant agreement will be allowed. Applicant agrees that failure to abide by terms and conditions of an approved grant may result in revocation of un-released grant funds, and future ineligibility for HHOW grants.

- ABSOLUTELY NO CHANGES OR EXCEPTIONS ALLOWED TO THE HHOW GRANT AGREEMENT. PLEASE DO NOT APPLY IF YOUR INSTITUTION WILL NOT AGREE TO THESE TERMS.